Simulations Plus Inc. (SLP) gains 1.29% for July 21

Equities Staff  |

Simulations Plus Inc. (NASDAQ: SLP) shares gained 1.29%, or $0.6 per share, to close Wednesday at $47.22. After opening the day at $46.82, shares of Simulations Plus fluctuated between $47.80 and $46.02. 84,948 shares traded hands a decrease from their 30 day average of 207,500. Wednesday's activity brought Simulations Plus’s market cap to $950,675,821.

About Simulations Plus Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. The company's technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide.

Visit Simulations Plus Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Simulations Plus Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Simulations Plus Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content